Hypoplastic Left Heart Syndrome Treatment Integrates Cardiac Stem Cells.

Initial trials of stem cell treatment for hypoplastic left heart syndrome have proven to be both safe and effective for children with the congenital defect.

Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell.  In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading

Stem Cells With a Heart of Gold.

Scientists use gold nanoparticles to improve stem cell transplants for heart disease patients.

A team of bioengineers from Tel Aviv University is currently developing a scaffold to help regenerate heart muscle through the use of autologous stem cells.  The scientists, led by Dr. Tal Dvir, aim to replace damaged cardiac tissue in heart attack patients by creating a scaffold out of collagen and gold nanoparticles, and then infusing it with the patient’s own stem cells to stimulate the rejuvenation of cardiomyocytes. Continue reading

Pulmonary Valve for Children Engineered from Stem Cells.

An organic pulmonary valve replacement for children has been engineered with stem cells to grow as the child does to prevent multiple surgeries.

Researchers at the University Of Maryland School Of Medicine have created a pulmonary valve replacement for pediatric patients suffering from congenital heart conditions.  The scientists, led by Dr. David L. Simpson, differentiated the patient’s own [autologous] stem cells into heart valvular cells and then arranged these cells to bioengineer a pulmonary valve that was unique to each patient.  The valve was created in vitro [outside the body] so the next step would be to develop protocols to undertake clinical trials.   Continue reading

New York Times: The Eruption of Stem Cell Therapies.

Mr. Edgar Irastorza is one of thousands of people already benefiting from the progression of stem cell based therapies.

As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years.  In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas. Continue reading

Mesoblast to Enter Phase III Clinical Trial for Heart Failure Stem Cell Treatment

 

 

 

 

 

 

 

 

Mesoblast, a leading stem cell technology and regenerative therapeutics company, received FDA approval to begin a Phase III clinical trial utilizing their stem cell therapy [Revascor] to treat heart failure.  We have reported on Mesoblast in previous posts; most recently, the announcement that they were developing neural related regenerative therapies utilizing dental pulp stem cells.

Continue reading

American Heart Association Reports on Stem Cell Clinical Trials

 

 

 

 

At this year’s American Heart Association Scientific Sessions, abstracts reporting on clinical trials involving the use of stem cells to treat various types of heart disease, such as Acute Myocardial Infarction and Ischemic Cardiomyopathy, were presented.

Continue reading